Sanofi has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, Sanofi’s phosphodiesterase type 4 (PDE4) inhibitor, in patients with Parkinson’s disease (PD). “AVE8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson’s disease, an area of unmet need where a new treatment could make...